Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab with ADT in Metastatic Prostate Cancer
NCT01120236Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cixutumumab in prostate cancer (PCa), sponsored by National Cancer Institute. Started Dec 2010; status: completed.
02
Drugs
cixutumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01120236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120236.